Clinical trials
Soft Tissue Infections clinical trials
Below are recruiting soft tissue infections clinical trials, each written for real people, not researchers. We’re tracking 120 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07243626RecruitingPhase 2
Envafolimab plus chemo for advanced soft tissue sarcoma
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
Hanzhong, ZhejiangAges 18 years+ - NCT07032285RecruitingPhase 2
Cirtuvivint for advanced soft-tissue sarcomas
This trial tests a new drug called Cirtuvivint for people with certain advanced soft-tissue sarcomas that have grown recently. It aims to see if the drug can stop or slow tumor growth.
Madrid, MadridAges 16–70 - NCT06980259Recruiting
Comparing two types of radiation for soft tissue sarcoma
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
Jinan, ShandongAges 18–70 - NCT05679921RecruitingPhase 2
Pazopanib, with or without pembrolizumab, for metastatic soft-tissue cancer
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
SeoulAges 20–80 - NCT04776525RecruitingPhase 2
Chemotherapy before surgery for certain soft tissue sarcomas
This trial tests a step-by-step (sequential) chemotherapy plan given before surgery for adults with specific types of soft tissue sarcoma. The goal is to shrink or control the tumor before the operation and see how well this approach works and is tolerated.
BergenAges 18 years+ - NCT06500065Recruiting
Testing a new PET scan for soft tissue sarcoma
This study uses a special PET/CT scan (68Ga-DOTATATE) to see if it can better find soft tissue sarcomas. You will also have a standard PET/CT scan for comparison, and the results may help guide your treatment.
Columbus, OhioAges 18 years+ - NCT04307277RecruitingPhase 3
Chemotherapy before and after surgery for high-risk soft tissue sarcoma
This trial tests whether giving chemotherapy both before and after surgery helps people with high-risk soft tissue sarcoma live longer and prevents the cancer from coming back. It aims to see if this treatment plan is more effective than surgery alone.
BesançonAges 18 years+ - NCT07619924Enrolling by invitationEarly Phase 1
Phage Cocktail for Hard-to-Treat Skin Infections
This study tests a new treatment called a phage cocktail (viruses that kill bacteria) for skin infections caused by bacteria that don't respond well to regular antibiotics. The treatment is applied directly to the wound to see if it's safe and effective.
Xi'an, ShaanxiAges 18–75 - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT06637007RecruitingPhase 2
Chidamide plus AK112 for advanced sarcoma after first treatment
This trial tests two new drugs (chidamide and AK112) together for people with advanced bone or soft tissue sarcoma that has not responded to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–75 - NCT05894018RecruitingPhase 2
Seed radiation plus fluzoparib for advanced soft tissue sarcoma
This trial tests whether combining seed radiation (iodine-125 placed in/near the tumor) with fluzoparib can better control advanced, hard-to-remove soft tissue sarcoma. It may help shrink tumors and slow progression, but you must meet several cancer, health, and safety requirements.
Guangzhou, GuangdongAges 18 years+ - NCT06849986RecruitingPhase 2
Immunotherapy & AI for first-line soft tissue sarcoma
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04605770RecruitingPhase 2
Pemetrexed and cisplatin for advanced soft tissue cancer
This Phase 2 trial tests whether pemetrexed plus cisplatin can shrink advanced or metastatic soft tissue sarcoma. It may help people whose cancer has spread and who can safely receive chemotherapy.
SeoulAges 19 years+ - NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT06760221Recruiting
Spotlight on bone cancer: SBRT plus surgery
This trial tests if giving a high dose of focused radiation (SBRT) before surgery can improve outcomes for people with aggressive soft tissue sarcoma in an arm or leg. You may be able to avoid chemotherapy and still have a good result.
Hangzhou, ZhejiangAges 18–80 - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06114004RecruitingPhase 2
Selinexor plus gemcitabine for advanced soft-tissue sarcoma
This trial tests a combination of two drugs, selinexor and gemcitabine, for people with a type of soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) that has spread or cannot be surgically removed and has gotten worse despite at least one prior treatment. The goal is to see if this combination can help shrink or slow the cancer.
Santa Cruz de Tenerife, Canary IslandsAges 18–80 - NCT06367075RecruitingPhase 2
Cadonilimab plus adriamycin for advanced soft tissue sarcoma
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
Wuhan, HubeiAges 18–75 - NCT07624331Recruiting
PEEK vs. Standard Healing Caps for Tooth Implants
This study compares two types of temporary healing caps (PEEK and standard materials) used during dental implant surgery for a single back tooth. Researchers will measure how well the gum tissue heals around each type to see which works better.
Sungai Buloh, SelangorAges 18 years+ - NCT07790770RecruitingPhase 1
A study of a new drug in healthy adults
This study tests a new drug called CMS-F021 in healthy volunteers. It aims to see how the drug behaves in the body after single and multiple doses.
BeijingAges 18–55 - NCT07359651Recruiting
Study on factors linked to death in severe tissue infections
This study looks at what factors are linked to higher risk of death in patients hospitalized with a severe, flesh-eating infection called necrotizing soft tissue infection (NSTI). It aims to help doctors better identify and treat these dangerous infections.
CagliariAges 18 years+ - NCT06877793Recruiting
Using dye imaging to diagnose severe flesh-eating infections
This trial tests a new way to quickly diagnose necrotizing soft tissue infections (NSTIs, also called flesh-eating infections) using a safe dye and a camera. If you are being checked for a possible NSTI, this could help doctors decide faster whether you have it and need treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07291297RecruitingPhase 2
Metformin plus standard therapy for soft tissue sarcoma
This trial tests adding metformin, a common diabetes drug, to the usual first cancer treatment for advanced soft tissue sarcoma. It may help the standard therapy work better.
Charlotte, North CarolinaAges 18 years+ - NCT06263231RecruitingPhase 3
Study of INT230-6 injection for soft tissue sarcoma
This study tests an experimental drug, INT230-6, injected directly into tumors, compared to the usual treatments for soft tissue sarcoma. It aims to see if the injection is safe and works better for people whose cancer has not responded to earlier treatments.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Soft Tissue Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for soft tissue infections?
- Yes. Clin2 currently lists 120 recruiting soft tissue infections studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a soft tissue infections trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a soft tissue infections trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.